NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis $28.65 +3.79 (+15.25%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tyra Biosciences Stock (NASDAQ:TYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tyra Biosciences alerts:Sign Up Key Stats Today's Range$24.51▼$29.5650-Day Range$24.86▼$33.0652-Week Range$11.70▼$40.65Volume1.86 million shsAverage Volume444,659 shsMarket Capitalization$1.71 billionP/E RatioN/ADividend YieldN/APrice Target$48.22Consensus RatingModerate Buy Company Overview Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need. The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection. Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.AI Generated. May Contain Errors. Read More Tyra Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreTYRA MarketRank™: Tyra Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 576th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTyra Biosciences has a consensus price target of $48.22, representing about 68.3% upside from its current price of $28.65.Amount of Analyst CoverageTyra Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tyra Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.74) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -11.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -11.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tyra Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.56% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 12.65, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently increased by 4.78%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.44 News SentimentTyra Biosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Tyra Biosciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for TYRA on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tyra Biosciences' insider trading history. Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TYRA Stock News HeadlinesTyra Bio rises on upcoming mid-stage trial readout for bladder cancer drugSeptember 4 at 3:42 PM | msn.comTYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug ReadoutSeptember 4 at 3:42 PM | msn.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle. | Traders Agency (Ad)Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026September 4 at 8:00 AM | prnewswire.comTyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer?August 31, 2026 | rttnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 31, 2026 | americanbankingnews.comTyra’s one-drug, three-indication bet nears its first phase 2 testAugust 21, 2026 | yahoo.comTyra Biosciences: SURF302 Is A Worthwhile Binary BetAugust 10, 2026 | seekingalpha.comSee More Headlines TYRA Stock Analysis - Frequently Asked Questions How have TYRA shares performed this year? Tyra Biosciences' stock was trading at $26.29 at the beginning of the year. Since then, TYRA stock has increased by 9.0% and is now trading at $28.65. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.04. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $162 million in an initial public offering (IPO) on the week of September 13th 2021. The company issued 10,800,000 shares at a price of $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Top institutional investors of Tyra Biosciences include Jupiter Topco LLC (7.29%), BlackRock Inc. (5.08%), 5AM Venture Management LLC (1.72%) and California State Teachers Retirement System (1.31%). Insiders that own company stock include Robert J More, Todd Harris, Nina S Kjellson, Daniel Bensen, Gilla Kaplan and Alan Fuhrman. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tyra Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/04/2026Today9/05/2026Study result9/09/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 2 days ago, TYRA's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TYRA CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees20Year Founded2018Price Target and Rating Average Price Target for Tyra Biosciences$48.22 High Price Target$56.00 Low Price Target$36.00 Potential Upside/Downside+68.3%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.39% Return on Assets-43.07% Debt Debt-to-Equity RatioN/A Current Ratio14.90 Quick Ratio14.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.93 per share Price / Book4.83Miscellaneous Outstanding Shares59,677,000Free Float52,217,000Market Cap$1.71 billion OptionableOptionable Beta0.73 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TYRA) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHow to Think About a $500K Roth Conversion and the 35% BracketFor 2026, the 35 percent federal tax bracket starts at 512,450 dollars in taxable income for joint filers and ...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
